A new trading day began on Friday, with BridgeBio Pharma Inc (NASDAQ: BBIO) stock price up 4.95% from the previous day of trading, before settling in for the closing price of $32.31. BBIO’s price has ranged from $21.62 to $39.47 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 574.82% over the past five years. Meanwhile, its annual earnings per share averaged -27.36%. With a float of $155.43 million, this company’s outstanding shares have now reached $190.04 million.
Let’s look at the performance matrix of the company that is accounted for 730 employees. In terms of profitability, gross margin is 97.67%, operating margin of -265.69%, and the pretax margin is -244.34%.
BridgeBio Pharma Inc (BBIO) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of BridgeBio Pharma Inc is 18.28%, while institutional ownership is 76.07%. The most recent insider transaction that took place on Apr 01 ’25, was worth 1,021,500. In this transaction Director of this company sold 30,000 shares at a rate of $34.05, taking the stock ownership to the 12,000 shares. Before that another transaction happened on Apr 01 ’25, when Company’s Director proposed sale 30,000 for $34.05, making the entire transaction worth $1,021,500.
BridgeBio Pharma Inc (BBIO) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -27.36% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 54.66% during the next five years compared to -3.04% drop over the previous five years of trading.
BridgeBio Pharma Inc (NASDAQ: BBIO) Trading Performance Indicators
Here are BridgeBio Pharma Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 4.67. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 29.06.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.85, a number that is poised to hit -0.91 in the next quarter and is forecasted to reach -2.60 in one year’s time.
Technical Analysis of BridgeBio Pharma Inc (BBIO)
BridgeBio Pharma Inc (NASDAQ: BBIO) saw its 5-day average volume 3.77 million, a positive change from its year-to-date volume of 3.09 million. As of the previous 9 days, the stock’s Stochastic %D was 66.12%. Additionally, its Average True Range was 2.24.
During the past 100 days, BridgeBio Pharma Inc’s (BBIO) raw stochastic average was set at 68.68%, which indicates a significant increase from 60.39% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 65.47% in the past 14 days, which was higher than the 63.89% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $33.60, while its 200-day Moving Average is $28.62. Nevertheless, the first resistance level for the watch stands at $34.69 in the near term. At $35.48, the stock is likely to face the second major resistance level. The third major resistance level sits at $36.87. If the price goes on to break the first support level at $32.51, it is likely to go to the next support level at $31.12. The third support level lies at $30.33 if the price breaches the second support level.
BridgeBio Pharma Inc (NASDAQ: BBIO) Key Stats
With a market capitalization of 6.45 billion, the company has a total of 190,189K Shares Outstanding. Currently, annual sales are 221,900 K while annual income is -535,760 K. The company’s previous quarter sales were 5,880 K while its latest quarter income was -265,050 K.
